Michael H. Mulroy - Net Worth and Insider Trading
Michael H. Mulroy Net Worth
The estimated net worth of Michael H. Mulroy is at least $451,627 dollars as of 2023-03-28. Michael H. Mulroy is the Director of Lineage Cell Therapeutics Inc and owns about 258,555 shares of Lineage Cell Therapeutics Inc (LCTX) stock worth over $359,391. Michael H. Mulroy is also the President and CEO of Asterias Biotherapeutics Inc and owns about 97,604 shares of Asterias Biotherapeutics Inc (AST) stock worth over $92,236. Details can be seen in Michael H. Mulroy's Latest Holdings Summary section.
Transaction Summary of Michael H. Mulroy
Michael H. Mulroy Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Michael H. Mulroy owns 4 companies in total, including Lineage Cell Therapeutics Inc (LCTX) , AgeX Therapeutics Inc (AGE) , and Asterias Biotherapeutics Inc (AST) among others .
Click here to see the complete history of Michael H. Mulroy’s form 4 insider trades.
Insider Ownership Summary of Michael H. Mulroy
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| LCTX | Lineage Cell Therapeutics Inc | 2014-10-04 | director |
| AGE | AgeX Therapeutics Inc | 2018-11-27 | director |
| AST | Asterias Biotherapeutics Inc | 2019-03-01 | director & President and CEO |
| CMRO | Comarco Inc | 2013-10-08 | director |
Michael H. Mulroy Latest Holdings Summary
Michael H. Mulroy currently owns a total of 2 stocks. Among these stocks, Michael H. Mulroy owns 258,555 shares of Lineage Cell Therapeutics Inc (LCTX) as of March 24, 2022, with a value of $359,391 and a weighting of 79.58%. Michael H. Mulroy also owns 97,604 shares of Asterias Biotherapeutics Inc (AST) as of August 27, 2018, with a value of $92,236 and a weighting of 20.42%.
Latest Holdings of Michael H. Mulroy
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| LCTX | Lineage Cell Therapeutics Inc | 2022-03-24 | 258,555 | 1.39 | 359,391 |
| AST | Asterias Biotherapeutics Inc | 2018-08-27 | 97,604 | 0.95 | 92,236 |
Holding Weightings of Michael H. Mulroy
Michael H. Mulroy Form 4 Trading Tracker
According to the SEC Form 4 filings, Michael H. Mulroy has made a total of 1 transactions in Lineage Cell Therapeutics Inc (LCTX) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Lineage Cell Therapeutics Inc is the acquisition of 7,000 shares on March 24, 2022, which cost Michael H. Mulroy around $9,800.
According to the SEC Form 4 filings, Michael H. Mulroy has made a total of 5 transactions in Asterias Biotherapeutics Inc (AST) over the past 5 years, including 5 buys and 0 sells. The most-recent trade in Asterias Biotherapeutics Inc is the acquisition of 3,141 shares on August 27, 2018, which cost Michael H. Mulroy around $4,994.
Insider Trading History of Michael H. Mulroy
- 1
Michael H. Mulroy Trading Performance
GuruFocus tracks the stock performance after each of Michael H. Mulroy's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Michael H. Mulroy is -17.39%. GuruFocus also compares Michael H. Mulroy's trading performance to market benchmark return within the same time period. The performance of stocks bought by Michael H. Mulroy within 3 months outperforms 2 times out of 13 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Michael H. Mulroy's insider trading performs compared to the benchmark.
Performance of Michael H. Mulroy
Average Relative Return
-53.93%
Outperforming Transactions
14%
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Relative Return(%) | -9.03 | -17.39 | -36.9 | -53.93 | ||
| Relative Return to S&P 500(%) | -9.44 | -18.27 | -35.64 | -53.92 |
Michael H. Mulroy Ownership Network
Ownership Network List of Michael H. Mulroy
Ownership Network Relation of Michael H. Mulroy
Michael H. Mulroy Owned Company Details
What does Lineage Cell Therapeutics Inc do?
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cell transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
Who are the key executives at Lineage Cell Therapeutics Inc?
Michael H. Mulroy is the director of Lineage Cell Therapeutics Inc. Other key executives at Lineage Cell Therapeutics Inc include Chief Financial Officer Jill Ann Howe , General Counsel/Secretary Samuel George A. Iii , and Chief Financial Officer Kevin Leon Cook .
Lineage Cell Therapeutics Inc (LCTX) Insider Trades Summary
Over the past 18 months, Michael H. Mulroy made 1 insider transaction in Lineage Cell Therapeutics Inc (LCTX) with a net purchase of 7,000. Other recent insider transactions involving Lineage Cell Therapeutics Inc (LCTX) include a net purchase of 930,106 shares made by Broadwood Partners Lp , a net sale of 539,283 shares made by Gary S. Hogge , and a net purchase of 35,000 shares made by Dipti Amin .
In summary, during the past 3 months, insiders sold 0 shares of Lineage Cell Therapeutics Inc (LCTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 539,283 shares of Lineage Cell Therapeutics Inc (LCTX) were sold and 977,356 shares were bought by its insiders, resulting in a net purchase of 438,073 shares.
Lineage Cell Therapeutics Inc (LCTX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Lineage Cell Therapeutics Inc Insider Transactions
Michael H. Mulroy Mailing Address
Above is the net worth, insider trading, and ownership report for Michael H. Mulroy. You might contact Michael H. Mulroy via mailing address: 1300 N. Kellogg Drive, Suite D, Anaheim Ca 92807.
